{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:13Z","timestamp":1792783333375,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza","id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01234-z","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:38:18Z","timestamp":1786124298000},"page":"657-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis"],"prefix":"10.1007","volume":"21","author":[{"given":"Mattia Alberto","family":"Di Civita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-9471","authenticated-orcid":false,"given":"Laura","family":"Pappalardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danila","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Stellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Zacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Gusmaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guadalupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Speranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"1234_CR1","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2020. https:\/\/gco.iarc.fr\/today."},{"issue":"2","key":"1234_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(12)70560-0.","journal-title":"Lancet Oncol"},{"issue":"10024","key":"1234_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)01037-5.","journal-title":"Lancet"},{"issue":"5","key":"1234_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686\u2013700. https:\/\/doi.org\/10.1016\/S1470-2045(19)30082-8.","journal-title":"Lancet Oncol"},{"issue":"32","key":"1234_CR5","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386. https:\/\/doi.org\/10.1200\/JCO.19.00799.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1234_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"N Engl J Med"},{"issue":"1","key":"1234_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307.","journal-title":"N Engl J Med"},{"issue":"36","key":"1234_CR8","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271\u201381. https:\/\/doi.org\/10.1200\/JCO-24-01798.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1234_CR9","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2119115.","journal-title":"N Engl J Med"},{"issue":"10318","key":"1234_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00336-3","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Maldonado X, Foulon S, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399(10318):1695\u2013707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00336-3.","journal-title":"Lancet"},{"issue":"4","key":"1234_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11523-022-00899-6","volume":"17","author":"C Verry","year":"2022","unstructured":"Verry C, Vincendeau S, Massetti M, Blachier M, Vimont A, Bazil ML, et al. Pattern of clinical progression until metastatic castration-resistant prostate cancer: an epidemiological study from the European Prostate Cancer Registry. Target Oncol. 2022;17(4):441\u201351. https:\/\/doi.org\/10.1007\/s11523-022-00899-6.","journal-title":"Target Oncol"},{"issue":"13","key":"1234_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/pros.24754","volume":"84","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Hoeh B, Hurst F, Koll F, Cano Garcia C, Humke C, et al. Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients. Prostate. 2024;84(13):1189\u201397. https:\/\/doi.org\/10.1002\/pros.24754.","journal-title":"Prostate"},{"issue":"4","key":"1234_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"N Matsubara","year":"2020","unstructured":"Matsubara N, Chi KN, \u00d6zg\u00fcro\u011flu M, Rodriguez-Antolin A, Feyerabend S, Fein L, et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. Eur Urol. 2020;77(4):494\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2019.11.021.","journal-title":"Eur Urol"},{"issue":"2","key":"1234_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.euo.2024.08.007","volume":"8","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Cano Garcia C, Humke C, Hoeh B, Steuber T, Tilki D, et al. Prostate-specific antigen nadir and cancer-control outcomes in real-world apalutamide-treated metastatic hormone-sensitive prostate cancer patients: a single-center analysis. Eur Urol Oncol. 2025;8(2):364\u201371. https:\/\/doi.org\/10.1016\/j.euo.2024.08.007.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"1234_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-78592-z","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Suo J, Wang B, Men Q, Wang D, Jing H, et al. Prognostic role of prostate specific antigen kinetics in primary high volume metastatic hormonal sensitive prostate cancer treated with novel hormonal therapy agents. Sci Rep. 2024;14(1):26712. https:\/\/doi.org\/10.1038\/s41598-024-78592-z.","journal-title":"Sci Rep"},{"issue":"2","key":"1234_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41391-023-00696-w","volume":"27","author":"G Gebrael","year":"2024","unstructured":"Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, et al. Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. Prostate Cancer Prostatic Dis. 2024;27(2):279\u201382. https:\/\/doi.org\/10.1038\/s41391-023-00696-w.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"1234_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10147-024-02676-z","volume":"30","author":"Y Yamada","year":"2025","unstructured":"Yamada Y, Sato K, Sakamoto S, Tsujino T, Saito S, Nishimura K, et al. Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors. Int J Clin Oncol. 2025;30(3):539\u201350. https:\/\/doi.org\/10.1007\/s10147-024-02676-z.","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"1234_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102140","volume":"22","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Shiraishi Y, Furukawa J, Okamura Y, Bando Y, Hara T, et al. Clinical outcomes and risk stratification in patients with metastatic hormone-sensitive prostate cancer treated with new-generation androgen receptor signaling inhibitors. Clin Genitourin Cancer. 2024;22(5):102140. https:\/\/doi.org\/10.1016\/j.clgc.2024.102140.","journal-title":"Clin Genitourin Cancer"},{"key":"1234_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.004","author":"A Tripathi","year":"2025","unstructured":"Tripathi A, Chen Y, Jarrard DF, Garcia JA, Dreicer R, Liu G, et al. Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Ann Oncol. 2025. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.004.","journal-title":"Ann Oncol"},{"issue":"1","key":"1234_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Jack Lee EJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8.","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"1234_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19422","volume":"13","author":"A Messori","year":"2021","unstructured":"Messori A. Synthetizing published evidence on survival by reconstruction of patient-level data and generation of a multi-trial Kaplan-Meier curve. Cureus. 2021;13(11):e19422. https:\/\/doi.org\/10.7759\/cureus.19422.","journal-title":"Cureus"},{"key":"1234_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"1","key":"1234_CR23","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.clgc.2023.07.012","volume":"22","author":"BHW Lam","year":"2024","unstructured":"Lam BHW, Tsang VHM, Lee MP, Chan K, Liu TC, Ng BYH, et al. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer. Clin Genitourin Cancer. 2024;22(1):e75-e85.e1. https:\/\/doi.org\/10.1016\/j.clgc.2023.07.012.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"1234_CR24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.euo.2025.06.010","volume":"8","author":"F Saad","year":"2025","unstructured":"Saad F, Briganti A, Haresh KP, Vjaters E, Olmos D, Littleton N, et al. A deep prostate-specific antigen response to darolutamide plus androgen deprivation therapy is associated with better clinical outcomes in the phase 3 ARANOTE trial in patients with metastatic hormone-sensitive prostate cancer. Eur Urol Oncol. 2025;8(5):1321\u201332. https:\/\/doi.org\/10.1016\/j.euo.2025.06.010.","journal-title":"Eur Urol Oncol"},{"issue":"16_Suppl","key":"1234_CR25","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1200\/JCO.2025.43.16_suppl.5092","volume":"43","author":"JS Freedland","year":"2025","unstructured":"Freedland JS, Gao W, Touya M, Yang H, Russel D. Chen J et al How low do you need to go? Association between various prostate-specific antigen (PSA) response measures and clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC) in the Veteran Health Administration (VHA) data. J Clin Oncol. 2025;43(16_Suppl):5092. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5092.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1234_CR26","first-page":"937","volume":"34","author":"P Pepe","year":"2014","unstructured":"Pepe P, Improta G, Fraggetta F, Emmanuele C, Simeon V, Dibenedetto G, et al. PSA nadir and outcome in 100 patients with pT3b prostate cancer. Anticancer Res. 2014;34(2):937\u201341.","journal-title":"Anticancer Res"},{"key":"1234_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-020-02111-3","volume":"19","author":"M Mustafa","year":"2021","unstructured":"Mustafa M, Rass HA, Yahya M, Hamdan K, Eiss Y. Primary metastatic prostate cancer between prognosis or adequate\/proper medical therapy. World J Surg Onc. 2021;19:5. https:\/\/doi.org\/10.1186\/s12957-020-02111-3.","journal-title":"World J Surg Onc"},{"issue":"8","key":"1234_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14737140.2020.1797497","volume":"20","author":"M Stellato","year":"2020","unstructured":"Stellato M, Guadalupi V, Sepe P, Mennitto A, Claps M, Zattarin E, et al. The emerging role of PARP inhibitors in prostate cancer. Expert Rev Anticancer Ther. 2020;20(8):715\u201326. https:\/\/doi.org\/10.1080\/14737140.2020.1797497.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"1234_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/03008916241270093","volume":"110","author":"A Rametta","year":"2024","unstructured":"Rametta A, Ambrosini P, Cavalli C, Gusmaroli E, Claps M, Giannatempo P, et al. Hot topics in genitourinary cancers: a multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy. Tumori. 2024;110(6):410\u20135. https:\/\/doi.org\/10.1177\/03008916241270093.","journal-title":"Tumori"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01234-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01234-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01234-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:51:42Z","timestamp":1790916702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01234-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1234"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01234-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mattia Alberto Di Civita, Laura Pappalardo, Danila De Angelis, Marco Stellato, Luca Zacco, Simone Rota, Eleonora Gusmaroli, Valentina Guadalupi, Iolanda Speranza, Michela Roberto, Elena Verzoni, Giuseppe Procopio, and Daniele Santini declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, consent to participate, consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Availability of data and material, code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization, M.A.D.C. and D.D.A.; methodology, M.A.D.C.; formal analysis, M.A.D.C.; resources, M.A.D.C. and D.D.A.; data curation, D.S. and L.P. and G.P. and E.V.; writing-original draft preparation, M.A.D.C. and L.P. writing-review and editing, M.S. and S.R. and G.V. and L.Z. and E.G. visualization, I.S. and M.R. supervision, D.S. and E.V. and G.P. All authors have read and agreed to the published version of the manuscript.","order":4,"name":"Ethics","label":"Authors' contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}